HEALTHCARE

The company’s solutions allow life sciences enterprises to move away from designing clinical trials based on subjective assumptions toward launching trials that have been tested, optimized, and de-risked.

The Israeli pharmaceutical company sees higher than expected sales of Austedo, Ajovy and Uzedy in 2026.

The new funds from the private placement will finance the company until 2030.

The company, a developer of cancer treatments using electric fields, handily beat the analysts on the top and bottom line, and reported success with new products.

The new three-year agreement for the supply of normal source plasma from Kamada's plasma collection centers in Texas will produce about $50 million in revenue over three years.

Despite the recent losses, analyst Ori Hershkovitz sees a 31% upside in the Israeli pharmaceutical company’s share price.

The German company will implement layoffs in Jerusalem and Rehovot.

The Israeli company’s AI model can analyze brain activity measured by non-invasive means and turn it into quantitative metrics designed to help doctors and researchers make diagnoses.

Private equity firm FIMI bought control of pharmaceuticals company Rafa Laboratories from the Sackler family in 2020.

Assaf Rappaport and the other Wiz founders seek to buy 25% of Herzliya Medical Center at a NIS 1 billion valuation, and a similar offer from Yitzhak Tshuva is still open, but regulation may thwart both contenders.

The Israeli company reported in the study that patients showed improvements in skin pigmentation with vitiligo.

IATI's annual report for 2025 portrays general stagnation in the Israeli industry. with one or two bright spots.

The investment comes following positive results in an initial efficacy trial, Phase IIa, in which an improvement in lung function was demonstrated in some 70% of patients.

The donation by the Jusidman family of Mexico will enable the Reuth Association to build its new rehabilitation hospital at Sde Dov.

Oran Holtzman's online cosmetics company was riding very high indeed until it hit a snag with its main advertising partner.

Teva had been in talks to sell its active pharmaceutical ingredients activity but a deal never materialized.

Former Teva CEO Jeremy Levin has published a sobering critique of a critical industry. He talks to "Globes" about his conclusions, and how Israel should act.

Dr. Marc Abitbol, who founded Jerusalem-based Visionix in 1994, tells “Globes” why he has finally decided to sell the eye care company and step down as CEO.

The company’s share price opened 22% higher today on Wall Street, giving a market cap of $984.5 million.

Reichman University’s Prof. Yosi Shacham-Diamand is developing chips that monitor plants, detect hazards in drinking water, and help medical teams treat wounded soldiers. Now he has an ambitious new vision.

In June 2025, an Iranian missile hit the Beersheva hospital's surgical wing, causing huge damage. The new plan includes three 30-floor towers.

The medical device company has developed an implant to protect healthy tissue from radiation damage during prostate cancer treatment.

The pharmaceutical company, controlled by FIMI, is one of the oldest in the Israeli economy.

The Israeli-German company has expanded from quantum sensing into quantum computing, advancing its efforts to build an end to end, quantum based approach to designing and validating therapies.

The Jerusalem hospital will be renamed the Koum Shaare Zedek Medical Center.

Dr. Henry and Dr. Susan Samueli have given $50 million to the Samueli Integrative Cancer Pioneering Institute at the hospital, following their initial $25 million donation to found the institute.
in the photo: Dr. Henry Samueli, Dr. Susan Samueli, Clalit Health Fund CEO Dr. Eitan Wertheim, and Prof. Gal Markel  credit: Koby Kuankas

The Israeli company analyzes more than 60 million patient cases annually in nearly 2,000 hospitals.

The Israeli pharmaceutical company has also announced first quarter results, which beat the analysts’ predictions.

The new agreement is a continuation of a collaboration between the parties, in which Ichilov transferred all of its computer systems to the cloud, becoming one of the world’s first hospitals to do so.

The company, which is building a new clinical infrastructure designed to close one of healthcare’s most costly and overlooked gaps, the 30 days following hospital discharge, has raised $20 million to date.